DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first current Good Manufacturing Practice (cGMP) microbial batches at its San Antonio manufacturing facility. This significant milestone marks the beginning of Scorpius' support for manufacturing programs through clinical manufacturing, with aspirations for future ...

At Scorpius Holdings, Inc's Annual Meeting of Shareholders (the "Annual Meeting") held on July 15, 2024, the Company's stockholders approved a proposal to amend the Company's certificate of incorporation to effect a reverse stock split of its Common Stock at a ratio of between 1-for-5 to 1-for-200, with the ratio within such range to be determined at the discretion of the Company's Board. Following the Annual Meeting, the Board approved a final split ratio of 1-for-200. Following the Reverse Stock Split, th ...

Forward-Looking Statement At Scorpius Holdings, Inc's Annual Meeting of Shareholders (the "Annual Meeting") held on July 15, 2024, the Company's stockholders approved a proposal to amend the Company's certificate of incorporation to effect a reverse stock split of its Common Stock at a ratio of between 1-for-5 to 1-for-200, with the ratio within such range to be determined at the discretion of the Company's Board. Following the Annual Meeting, the Board approved a final split ratio of 1-for-200. Following t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 29, 2024 Scorpius Holdings, Inc. (Exact name of registrant as specified in charter) Delaware 001-35994 26-2844103 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 627 Davis Drive, Suite 300 Morrisville, North Carolina 27560 (Address of principal exe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-35994 Scorpius Holdings, Inc. (Exact name of registrant as specified in its c ...

| | | UNITED | | | |--------------|-----------------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------|----------------------------------------| | | | SECURITIES AND | COMMISSION | | | | | Washington, | | | | | | FORM | | | | ☑ | ANNUAL REPORT PURSUANT TO | SECTION 13 OR 15(d) OF | SECURITIES EXCHANGE ACT | OF 1934 | | | | For the fiscal year ended | 31, 2023 | | | | | OR | | | | ☐ | TRANSITION REPOR ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 7, 2024 Scorpius Holdings, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-35994 26-2844103 (Commission File Number) (IRS Employer Identification No.) 627 Davis Drive, Suite 400 Morrisville, North Carolina 27560 (Address ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-35994 NightHawk Biosciences, Inc. (Exact name of registrant as specified ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-35994 | NightHawk | |-----------------------------------------| | (Exact name of registrant as | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-35994 NightHawk Biosciences, Inc. (Exact name of registrant as specified in its charter) Delawa ...